Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration

Abstract

Imatinib mesylate (Gleevec, Glivec, formerly, STI571) is an inhibitor of the BCR-ABL tyrosine kinase that is central to the pathogenesis of chronic myelogenous leukemia (CML). A recent large-scale prospective randomized trial, comparing imatinib vs interferon plus cytarabine for chronic phase CML, demonstrated the impressive therapeutic superiority of… (More)
DOI: 10.1038/sj.leu.2403251

Topics

2 Figures and Tables